Top Markets
#1 Black Phoenix Black Phoenix +1,222.69%
#2 inSure DeFi inSure DeFi +73.80%
#3 tomiNet tomiNet +59.76%
#4 哈基米 (Hakimi) 哈基米 (Hakimi) +51.81%
#5 aPriori aPriori +51.05%
#6 Bedrock Bedrock +46.41%
#7 Akedo Akedo +42.10%
#8 HOPR HOPR +34.23%
#9 PUMPCADE PUMPCADE +31.72%
#10 ChainOpera AI ChainOpera AI +29.96%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Rank in Stocks #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Share Price
$193.62
Market Cap
$150.08B
Change (1 day)
2.76%
Change (1 year)
184.69%
Country
GB
Trade AstraZeneca PLC (AZN)

Category

Healthcare
Number of shares outstanding for AstraZeneca PLC (AZN)
Number of shares outstanding as of December 2025: 3.10B
According to AstraZeneca PLC latest financial reports and stock price the company's current number of shares outstanding is 3.10B. At the end of December 2024 the company had 3.10B shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for AstraZeneca PLC (AZN) from 2000 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 3.10B 0.00%
2025 3.10B 0.00%
2024 3.10B -0.77%
2023 3.12B 0.90%
2022 3.10B 9.17%
2021 2.84B 8.08%
2020 2.62B 0.85%
2019 2.60B 2.68%
2018 2.53B 0.08%
2017 2.53B 0.08%
2016 2.53B 0.08%
2015 2.53B 0.16%
2014 2.52B 0.80%
2013 2.50B -0.71%
2012 2.52B -7.35%
2011 2.72B -5.35%
2010 2.88B -0.69%
2009 2.90B -0.34%
2008 2.91B -2.81%
2007 2.99B -4.41%
2006 3.13B -3.28%
2005 3.23B -3.35%
2004 3.35B -2.11%
2003 3.42B -1.38%
2002 3.47B -1.42%
2001 3.52B -0.57%
2000 3.54B 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 898.00M -71.03%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 2.43B -21.66%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 1.78B -42.57%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 1.91B -38.29%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 2.49B -19.68%
US